Skip to main content
Equibles

UBS Group AG

Position in VTRS — Viatris Inc

CIK 1610520 ZURICH, V8
Back to VTRS Full portfolio

Position in VTRS

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$44,009,240
+$22,486,418 QoQ
Shares Held
3,257,531
+88.4% QoQ
Ownership
0.280%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2020
22 quarters on record
Voting authority Sole 64.79794052612239.ToString("F0")% Shared 0.ToString("F0")% None 35.202059473877604.ToString("F0")%

Common Shares in VTRS Over Time

Shares Held

Position Value (USD)

Derivatives in VTRS

reported options exposure · as of Mar 31, 2026
CallValue
$1,351
CallShares
100
PutValue
$248,584
PutShares
18,400

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

UBS Group AG holds $1,524,520,292 across 81 Drug Manufacturers - Specialty & Generic names. VTRS ranks #11 (2.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ZTS
Zoetis Inc.
 2,799,543 $330,933,975
2 ELAN
Elanco Animal Health Inc
 8,572,057 $205,129,322
3 NBIX
Neurocrine Biosciences Inc
 1,221,036 $160,859,281
4 UTHR
UNITED THERAPEUTICS Corp
 236,729 $140,375,559
5 HIMS
Hims & Hers Health, Inc.
 4,151,638 $86,188,003
6 INDV
Indivior Pharmaceuticals, Inc.
 2,192,264 $66,820,205
7 LNTH
Lantheus Holdings, Inc.
 867,675 $65,813,148
8 TEVA
Teva Pharmaceutical Industries Ltd
 1,877,217 $56,541,775

All Filings in VTRS

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $248,584 18,400
2026-03-31 $1,351 100
2026-03-31 $44,009,240 3,257,531
2025-12-31 $21,522,822 1,728,741
2025-12-31 $229,080 18,400
2025-12-31 $1,245 100
2025-09-30 $45,379,212 4,583,759
2025-06-30 $51,431,430 5,759,399
2025-03-31 $44,721,569 5,134,509
2024-12-31 $46,984,293 3,773,839
2024-09-30 $28,135,019 2,423,344
2024-06-30 $1,330,876 125,200
2024-06-30 $23,511,663 2,211,822
2024-03-31 $22,665,282 1,898,265
2023-12-31 $334,647 30,900
2023-12-31 $28,742,873 2,654,005
2023-12-31 $5,060,859 467,300
2023-09-30 $37,084,759 3,761,132
2023-09-30 $304,674 30,900
2023-09-30 $4,607,578 467,300
2023-06-30 $29,982,482 3,004,257
2023-06-30 $408,182 40,900
2023-06-30 $3,765,454 377,300
2023-03-31 $31,352,511 3,259,097
2023-03-31 $6,465,602 672,100
2023-03-31 $4,160,650 432,500
2022-12-31 $14,345,457 1,288,900
2022-12-31 $27,324,625 2,455,043
2022-12-31 $11,985,897 1,076,900
2022-09-30 $9,933,468 1,165,900
2022-09-30 $27,142,025 3,185,684
2022-09-30 $2,766,444 324,700
2022-06-30 $5,848,542 558,600
2022-06-30 $23,280,045 2,223,500
2022-06-30 $18,169,594 1,735,396
2022-03-31 $4,107,200 377,500
2022-03-31 $16,044,961 1,474,721
2022-03-31 $3,264,000 300,000
2021-12-31 $25,723,384 1,901,211
2021-12-31 $29,584,450 2,186,582
2021-12-31 $17,589,460 1,300,034
2021-09-30 $27,151,920 2,003,832
2021-09-30 $8,130,000 600,000
2021-09-30 $26,431,253 1,950,646
2021-06-30 $40,347,684 2,823,491
2021-06-30 $8,574,000 600,000
2021-06-30 $30,740,976 2,151,223
2021-03-31 $44,770,887 3,204,788
2021-03-31 $34,996,344 2,505,107
2020-12-31 $54,153,483 2,889,727

Report a Problem

Category
Description
Email (optional, for follow-up)